Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CSF GABA in psychotic disorders.

M B Bowers, B I Gold, R H Roth

    Psychopharmacology
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Cerebrospinal fluid (CSF) gamma-aminobutyric acid (GABA) levels did not differ in psychotic patients compared to controls. However, in untreated patients, GABA correlated with anxiety, and in treated patients, it correlated with homovanillic acid (HVA).

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Clozapine in the treatment of aggression in an adolescent with autistic disorder.

    The Journal of clinical psychiatry·2001
    Same author

    Antidepressant-associated mania and psychosis resulting in psychiatric admissions.

    The Journal of clinical psychiatry·2001
    Same author

    Rab27a enables myosin Va-dependent melanosome capture by recruiting the myosin to the organelle.

    Journal of cell science·2001
    Same author

    Lamotrigine as prophylaxis against steroid-induced mania.

    The Journal of clinical psychiatry·1999
    Same author

    Interactive effects of subanesthetic ketamine and haloperidol in healthy humans.

    Psychopharmacology·1999
    Same author

    Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.

    Journal of clinical psychopharmacology·1999
    Same journal

    GlyT1 inhibition enhances working memory in the mouse TUNL task and normalizes NMDA antagonist-induced network activity.

    Psychopharmacology·2026
    Same journal

    Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.

    Psychopharmacology·2026
    Same journal

    Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CB<sub>1</sub> and 5-HT<sub>1A</sub> receptor signaling.

    Psychopharmacology·2026
    Same journal

    Fentanyl decreases arterial blood oxygen saturation more than furanylfentanyl in mice due to increased apnea.

    Psychopharmacology·2026
    Same journal

    Suicide attempt risk among patients receiving methylphenidate: a retrospective cohort study.

    Psychopharmacology·2026
    Same journal

    Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

    Psychopharmacology·2026
    See all related articles

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Biochemistry

    Background:

    • Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system.
    • Altered GABAergic function has been implicated in the pathophysiology of psychosis.
    • Understanding GABA levels in relation to psychotic disorders and antipsychotic treatment is crucial.

    Purpose of the Study:

    • To investigate cerebrospinal fluid (CSF) GABA levels in drug-free psychotic patients.
    • To compare CSF GABA levels between untreated psychotic patients, treated psychotic patients, and a neurological comparison group.
    • To explore correlations between CSF GABA levels and clinical symptoms or other neurochemical markers.

    Main Methods:

    • CSF samples were collected from three groups: drug-free psychotic patients, psychotic patients undergoing haloperidol treatment (at two time points), and a neurological comparison group.

    Related Experiment Videos

  • CSF GABA levels were quantified.
  • Correlations between CSF GABA and clinical ratings (anxiety, agitation) and CSF homovanillic acid (HVA) were analyzed.

    • Main Results:

    • No significant differences in CSF GABA levels were found between the drug-free psychotic group, the treated psychotic groups, or the neurological comparison group.
    • In the untreated psychotic group, CSF GABA levels showed a significant negative correlation with clinical ratings of anxiety and agitation.
    • Early in haloperidol treatment, CSF GABA levels were significantly positively correlated with CSF HVA.

    Conclusions:

    • CSF GABA levels do not appear to be significantly altered in psychosis itself, irrespective of treatment status.
    • CSF GABA may be associated with anxiety and agitation symptoms in untreated psychosis.
    • A potential relationship between GABA and dopamine turnover (indicated by HVA) emerges during haloperidol treatment.